- This event has passed.
ITMAT Meeting: Big Data and the Development of New Medicines
17/03/2017 @ 8:00 am - 5:10 pm
Registration and abstract submission are open for the Institute for Translational Medicine & Therapeutics (ITMAT) in Edinburgh Meeting, which will be held on ‘Big Data & the Development of New Medicines’ on Friday 17 March 2017 at the Royal College of Physicians of Edinburgh conference centre.
The one-day programme will bring together a faculty of internationally-recognised speakers, thanks to support from the British Pharmacological Society and the Royal Society of Edinburgh. The organisers look forward to welcoming both early and established researchers, from across science and medicine.
- Dr Neeraj Dhaun, British Heart Foundation Intermediate Clinical Research Fellow, University of Edinburgh, UK
- Professor Garret FitzGerald, Professor of Medicine & Systems Pharmacology & Translational Therapeutics and Director, ITMAT, University of Pennsylvania, USA
- Professor Sir John Savill, Chief Executive, Medical Research Council, UK and Professor of Experimental Medicine, Vice Principal and Head of College of Medicine & Veterinary Medicine, University of Edinburgh, UK
- Professor David Webb, President, British Pharmacological Society and Christison Professor of Therapeutics & Clinical Pharmacology, University of Edinburgh, UK
Non-member registration – £95
Click to view the ITMAT flyer
Abstract submission deadline: 31 January
Full details about how to submit your research before the deadline are available online.
Bursary application deadline: 31 January
Applications are welcome from members of the British Pharmacological Society who have submitted research for presentation at the ITMAT Meeting. Further details about the application process and criteria are available online (member sign in required).
This is the first time that the ITMAT Meeting has been held in Europe: ITMAT is directed by Professor Garret FitzGerald HonFBPhS and based at the Perelman School of Medicine, University of Pennsylvania, and was the first institute for translational medicine in the world. It supports work at the interface of basic and clinical research, focusing on developing new and safer medicines.